Symphogen Appoints Adriann Sax Chief Business Officer - Gilde Healthcare

Symphogen Appoints Adriann Sax Chief Business Officer

August 17, 2009

Seasoned Executive will Drive Business Development Efforts for Antibody Discovery and Expression Platforms

COPENHAGEN, Denmark – Symphogen A/S today announced that Adriann Sax has joined the company’s management team as Chief Business Officer.

Ms. Sax brings to Symphogen extensive experience in corporate and business development and has held several executive and management positions at leading biotechnology and pharmaceutical companies.

“Adriann’s demonstrated leadership skills in the areas of strategic, operational and portfolio planning, capital raising, and alliance building and cultivation all make her a perfect fit for Symphogen at this important point in our company’s evolution,”

said Kirsten Drejer, Ph.D., CEO of Symphogen.

Ms. Sax added,

“I look forward to supporting Symphogen’s business objectives for its novel pipeline and antibody discovery and expression platforms. By capturing the diversity and specificity of the natural human immune response, Symphogen creates recombinant fully human monoclonal and polyclonal antibodies, with demonstrated advantages over other antibody approaches. I believe that these advantages will translate into more potent therapeutic effects in the treatment of serious diseases and will be an important asset for potential corporate partners who seek to strengthen their internal therapeutic antibody programs.”

Before Symphogen, Adriann most recently served as Executive Vice President, Corporate Strategy, Strategic Marketing and Alliances at King Pharmaceuticals. Prior to this most recent position, she served as Executive Vice President, Business Development and Strategic Planning at King leading many successful transactions. With over 25 years of pharmaceutical experience, Adriann has held leadership roles at Merck, Bristol-Myers Squibb, Roche Laboratories and Sterling Drug and made many important contributions in the areas of oncology, transplantation and diagnostic imaging.

Adriann is also recognized for her ongoing commitment to the professional development and advancement of women within the pharmaceutical industry. She serves as a Director on the National Advisory Board of the Healthcare Businesswomen’s Association and Foundation Associate of the Women Business Leaders of the U.S. Healthcare Foundation. In 2008, Adriann was named as one of the Top 100 Most Inspiring Leaders in the Life Sciences Industry by PharmaVoice Magazine.

Ms. Sax holds an MBA in Marketing from the Keller Graduate School of Management and a BS in Veterinary Medicine from the University of Delaware.

About Symphogen
Symphogen is developing superior antibody therapeutics to help people with serious diseases. With its proprietary SymplexTM discovery and SympressTM manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions. Symphogen is maturing a diversified pipeline of internal and partnered products across multiple indications including cancer and infectious disease. Symphogen is a private biopharmaceutical company with more than 70 employees, based in Copenhagen, Denmark. www.symphogen.com

Contacts
Kirsten Drejer, CEO of Symphogen
+45 45 26 50 59 or +45 22 10 99 59 (cell)
kd@symphogen.com

Gilde Healthcare company LAVA Therapeutics announces exclusive worldwide license agreement with Seagen to advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta...
September 26, 2022

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022